Dna Methylation is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
DNA methylation is an epigenetic modification involving the addition of a methyl group to the 5-position of cytosine residues in DNA (forming 5-methylcytosine, 5mC). This reversible, heritable modification regulates gene expression without altering the underlying DNA sequence and plays crucial roles in brain development, neuronal identity, synaptic plasticity, and aging. Aberrant DNA methylation patterns are increasingly recognized as a core feature of Alzheimer's disease and other neurodegenerative disorders, linking environmental exposures and aging to altered gene expression and neuronal vulnerability (Coppieters et al., 2014; Day & Bhatt, 2024). [1]
DNA methylation is part of a broader epigenetic landscape that includes histone modifications, non-coding RNA regulation, and chromatin remodeling, all of which interact to determine gene expression states in the aging and diseased brain. [2]
Three major DNMT enzymes catalyze methylation reactions (Portela & Esteller, 2010): [3]
| Enzyme | Type | Key Function | Brain Expression | [4]
|--------|------|-------------|-----------------| [5]
| DNMT1 | Maintenance | Copies methylation patterns to daughter strands during DNA replication | High in post-mitotic Neurons; maintains neuronal identity | [6]
| DNMT3A | De novo | Establishes new methylation marks | Active in adult neurogenesis and synaptic plasticity | [7]
| DNMT3B | De novo | Establishes methylation during embryonic development | Lower postnatal expression; variants linked to ICF syndrome | [8]
| DNMT3L | Regulatory | Stimulates DNMT3A/B activity; lacks catalytic domain | Important in genomic imprinting | [9]
DNA methylation is a dynamic, reversible process: [10]
5-hydroxymethylcytosine (5hmC) is particularly abundant in the brain — approximately 10-fold higher than other tissues — and is enriched at active gene bodies and enhancers, where it serves as a stable epigenetic mark rather than merely a transient intermediate (Globisch et al., 2010). [11]
| Methylation Context | Effect on Expression | Brain Relevance |
|---|---|---|
| CpG island promoters | Methylation → silencing | Controls expression of synaptic and neuronal identity genes |
| Gene bodies | Methylation → active transcription | Regulates alternative splicing; enriched for 5hmC in Neurons |
| Enhancers | Cell-type-specific methylation patterns | Determines neurons vs. glia] gene expression programs |
| Non-CpG (CpH) methylation | Unique to Neurons; brain-specific | Accumulates during postnatal brain maturation; may regulate neuronal gene expression |
| Repetitive elements | Methylation maintains silencing | Loss of methylation at LINE-1 elements linked to aging and neurodegeneration |
The brain exhibits unique methylation characteristics not seen in other tissues:
High 5hmC levels: Brain has the highest 5hmC content of any organ, particularly in Neurons of the cortex, hippocampus, and cerebellum
Non-CpG methylation: Neurons accumulate substantial CpH methylation (CpA, CpT, CpC) during postnatal development — a feature unique to brain cells
Cell-type specificity: Dramatic differences in methylation patterns between Neurons, Astrocytes, [microglia:
Global DNA hypomethylation in vulnerable regions (hippocampus, entorhinal cortex, [prefrontal [cortex)
Reduced 5hmC levels, particularly in hippocampal Neurons
Epigenome-wide association studies (EWAS) have identified hundreds of differentially methylated positions (DMPs) associated with AD neuropathology
Cell-type deconvolution reveals that many DMPs in bulk cortex tissue reflect methylation changes in non-neuronal cells (microglia/cell-types/microglia:**
BDNF: Reduced trophic support for hippocampal and cortical Neurons
ANK1: Consistently identified as hypermethylated in the entorhinal cortex; one of the most robust EWAS findings in AD
HOXA3, BIN1, RHBDF2: Genome-wide significant DMPs replicated across multiple cohorts
SYP, CREB: Synaptic plasticity genes with reduced expression
Hypomethylated genes (activated in AD):
DNMT inhibitors:
TET enzyme modulators:
HDAC inhibitors]:
Modifiable factors that influence brain DNA methylation:
The study of Dna Methylation has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration/mechanisms) and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28:1057-1068. PubMed. 2010. ↩︎
Globisch D, et al. Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. PLoS One. 2010;5:e15367. PubMed. 2010. ↩︎
Day JJ, Sweatt JD. Epigenetic mechanisms in cognition. Nat Rev Neurosci. 2015;16:661-675. PubMed. 2015. ↩︎
Day K, Bhatt DK. DNA methylation: the epigenetic mechanism of Alzheimer''s Disease. Neurosci Bull. 2024. PubMed. 2024. ↩︎
Horvath S. DNA methylation age of human tissues and cell types/cell-types). Genome Biol. 2013;14:R115. . DOI. 2013. ↩︎
Smart E, et al. Epigenetic regulation in neurodegeneration. J Neurochem. 2018;144:124-138. PubMed. 2018. ↩︎
Levine ME, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging. 2018. ↩︎
npj Dementia. DNA methylation age from peripheral blood predicts progression to Alzheimer's Disease. npj Dementia. 2025. . DOI. 2025. ↩︎
Lord J, Cruchaga C. The epigenetic landscape of Alzheimer's Disease. Nat Neurosci. 2014. ↩︎